{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T18:40:16Z","timestamp":1793990416932,"version":"4.8.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s13555-025-01434-x","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T14:51:19Z","timestamp":1748530279000},"page":"2047-2059","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tildrakizumab Treatment Patterns in Adults With Moderate-to-Severe Plaque Psoriasis: A Retrospective Analysis From the Canadian Patient Support Program"],"prefix":"10.1007","volume":"15","author":[{"given":"Vimal H.","family":"Prajapati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Bellefontaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devi","family":"Gopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rommel","family":"Mangaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pak","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell B.","family":"Sauder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"issue":"4","key":"1434_CR1","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1434_CR2","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s13555-021-00518-8","volume":"11","author":"KA Papp","year":"2021","unstructured":"Papp KA, Gniadecki R, Beecker J, et al. Psoriasis prevalence and severity by expert elicitation. Dermatol Ther (Heidelb). 2021;11(3):1053\u201364.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1434_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/jdv.13854","volume":"31","author":"IM Michalek","year":"2017","unstructured":"Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205\u201312.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1434_CR4","first-page":"19","volume":"4","author":"SN Pathak","year":"2014","unstructured":"Pathak SN, Scott PL, West C, Feldman SR. Self-management in patients with psoriasis. Psoriasis (Auckl). 2014;4:19\u201326.","journal-title":"Psoriasis (Auckl)"},{"issue":"1","key":"1434_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/bjd.16332","volume":"179","author":"CEM Griffiths","year":"2018","unstructured":"Griffiths CEM, Jo SJ, Naldi L, et al. A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. Br J Dermatol. 2018;179(1):173\u201381.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1434_CR6","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1365-2133.2005.06502.x","volume":"152","author":"AY Finlay","year":"2005","unstructured":"Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152(5):861\u20137.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1434_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/09546634.2013.865009","volume":"26","author":"RG Langley","year":"2015","unstructured":"Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator\u2019s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26(1):23\u201331.","journal-title":"J Dermatolog Treat"},{"issue":"10091","key":"1434_CR8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276\u201388.","journal-title":"Lancet"},{"issue":"4","key":"1434_CR9","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis\u2013results of two phase 3 trials. N Engl J Med. 2014;371(4):326\u201338.","journal-title":"N Engl J Med"},{"issue":"10","key":"1434_CR10","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamadermatol.2024.2701","volume":"160","author":"AW Armstrong","year":"2024","unstructured":"Armstrong AW, Gooderham M, Lynde C, et al. Tyrosine kinase 2 inhibition with zasocitinib (TAK-279) in psoriasis: a randomized clinical trial. JAMA Dermatol. 2024;160(10):1066\u201374.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"1434_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/2040622318759282","volume":"9","author":"TC Chan","year":"2018","unstructured":"Chan TC, Hawkes JE, Krueger JG. Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment. Ther Adv Chronic Dis. 2018;9(5):111\u20139.","journal-title":"Ther Adv Chronic Dis"},{"key":"1434_CR12","unstructured":"PrILUMYA\u2122 tildrakizumab injection. 100 mg in 1 mL sterile solution (100 mg\/mL) for subcutaneous injection. Product monograph. Brampton, ON, Canada: Sun Pharma Canada Inc.; 2022."},{"key":"1434_CR13","unstructured":"ILUMYA\u00ae (tildrakizumab-asmn) injection, for subcutaneous use. Full prescribing information. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2024."},{"key":"1434_CR14","unstructured":"European Medicines Agency. Ilumetri. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ilumetri. Accessed 12 Aug 2024."},{"key":"1434_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2147\/CCID.S402183","volume":"16","author":"A Ruggiero","year":"2023","unstructured":"Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M. Tildrakizumab for the treatment of moderate-to-severe psoriasis: results from 52 weeks real-life retrospective study. Clin Cosmet Investig Dermatol. 2023;16:529\u201336.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"4","key":"1434_CR16","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1304a215","volume":"13","author":"EV Di Brizzi","year":"2023","unstructured":"Di Brizzi EV, Buononato D, Benvenuto P, et al. Effectiveness and safety after a switch to tildrakizumab: a real world multicenter Italian study in psoriasis. Dermatol Pract Concept. 2023;13(4): e2023215.","journal-title":"Dermatol Pract Concept"},{"issue":"4","key":"1434_CR17","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3390\/ph16040526","volume":"16","author":"E Campione","year":"2023","unstructured":"Campione E, Lambiase S, Gaeta Shumak R, et al. A real-life study on the use of tildrakizumab in psoriatic patients. Pharmaceuticals (Basel). 2023;16(4):526.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"1434_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1177\/24755303221077211","volume":"7","author":"NW Wei","year":"2022","unstructured":"Wei NW, Chi S, Lebwohl MG. Retrospective analysis in patients with moderate to severe plaque psoriasis treated with tildrakizumab: real-life clinical data. J Psoriasis Psoriatic Arthritis. 2022;7(2):55\u20139.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"1","key":"1434_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/jdv.18594","volume":"37","author":"A Narcisi","year":"2023","unstructured":"Narcisi A, Valenti M, Gargiulo L, et al. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis). J Eur Acad Dermatol Venereol. 2023;37(1):93\u2013103.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1434_CR20","doi-asserted-by":"publisher","first-page":"15078","DOI":"10.1038\/s41598-022-18790-9","volume":"12","author":"T Graier","year":"2022","unstructured":"Graier T, Weger W, Jonak C, et al. Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA). Sci Rep. 2022;12(1):15078.","journal-title":"Sci Rep"},{"issue":"9","key":"1434_CR21","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s13555-022-00775-1","volume":"12","author":"A Armstrong","year":"2022","unstructured":"Armstrong A, Xia Q, John AR, Patel V, Seigel L. Treatment patterns for targeted therapies, non-targeted therapies, and drug holidays in patients with psoriasis. Dermatol Ther (Heidelb). 2022;12(9):2087\u2013103.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"11","key":"1434_CR22","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/1346-8138.16543","volume":"49","author":"Y Tada","year":"2022","unstructured":"Tada Y, Kim H, Spanopoulos D, et al. Treatment patterns, healthcare resource utilization, and costs in patients with moderate-to-severe psoriasis treated with systemic therapy in Japan: a retrospective claims database study. J Dermatol. 2022;49(11):1106\u201317.","journal-title":"J Dermatol"},{"issue":"1","key":"1434_CR23","doi-asserted-by":"publisher","first-page":"2200870","DOI":"10.1080\/09546634.2023.2200870","volume":"34","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Patel M, Li C, Garg V, Mandava MR, Wu JJ. Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States. J Dermatolog Treat. 2023;34(1):2200870.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1434_CR24","doi-asserted-by":"publisher","first-page":"2176708","DOI":"10.1080\/09546634.2023.2176708","volume":"34","author":"S Thai","year":"2023","unstructured":"Thai S, Zhuo J, Zhong Y, et al. Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies. J Dermatolog Treat. 2023;34(1):2176708.","journal-title":"J Dermatolog Treat"},{"issue":"7","key":"1434_CR25","first-page":"770","volume":"25","author":"D Brixner","year":"2019","unstructured":"Brixner D, Rubin DT, Mease P, et al. Patient support program increased medication adherence with lower total health care costs despite increased drug spending. J Manag Care Spec Pharm. 2019;25(7):770\u20139.","journal-title":"J Manag Care Spec Pharm"},{"key":"1434_CR26","first-page":"711","volume":"10","author":"A Ganguli","year":"2016","unstructured":"Ganguli A, Clewell J, Shillington AC. The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic review. Patient Prefer Adherence. 2016;10:711\u201325.","journal-title":"Patient Prefer Adherence"},{"issue":"8","key":"1434_CR27","first-page":"859","volume":"23","author":"DT Rubin","year":"2017","unstructured":"Rubin DT, Mittal M, Davis M, Johnson S, Chao J, Skup M. Impact of a patient support program on patient adherence to adalimumab and direct medical costs in Crohn\u2019s disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis. J Manag Care Spec Pharm. 2017;23(8):859\u201367.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"1434_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s13555-022-00853-4","volume":"13","author":"W Gulliver","year":"2023","unstructured":"Gulliver W, Gooderham MJ, Zhu B, et al. Treatment persistence of ixekizumab in adults with moderate-to-severe plaque psoriasis participating in the Canadian patient support program. Dermatol Ther (Heidelb). 2023;13(1):235\u201344.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"1434_CR29","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.3390\/jcm11061506","volume":"11","author":"E Piragine","year":"2022","unstructured":"Piragine E, Petri D, Martelli A, et al. Adherence and persistence to biological drugs for psoriasis: systematic review with meta-analysis. J Clin Med. 2022;11(6):1506.","journal-title":"J Clin Med"},{"issue":"3","key":"1434_CR30","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1159\/000519176","volume":"238","author":"C Xu","year":"2022","unstructured":"Xu C, Teeple A, Wu B, Fitzgerald T, Feldman SR. Drug adherence and persistence of patients with moderate to severe psoriasis treated with biologic medications in a US commercially insured population. Dermatology. 2022;238(3):438\u201347.","journal-title":"Dermatology"},{"issue":"1","key":"1434_CR31","doi-asserted-by":"publisher","first-page":"2349658","DOI":"10.1080\/09546634.2024.2349658","volume":"35","author":"M Zhdanava","year":"2024","unstructured":"Zhdanava M, Fitzgerald T, Pilon D, et al. Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States. J Dermatolog Treat. 2024;35(1):2349658.","journal-title":"J Dermatolog Treat"},{"issue":"10","key":"1434_CR32","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","volume":"158","author":"ZZN Yiu","year":"2022","unstructured":"Yiu ZZN, Becher G, Kirby B, et al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022;158(10):1131\u201341.","journal-title":"JAMA Dermatol"},{"key":"1434_CR33","unstructured":"PrSTELARA\u00ae ustekinumab injection. Solution for subcutaneous injection. 45 mg\/0.5 mL and 90 mg\/1.0 mL. Product monograph. Toronto, ON, Canada: Janssen Inc.; 2023."},{"key":"1434_CR34","unstructured":"PrWEZLANA\u00ae ustekinumab injection. Solution for subcutaneous injection. 45 mg\/0.5 mL and 90 mg\/1.0 mL. Product monograph. Mississauga, ON, Canada: Amgen Canada Inc.; 2023."},{"key":"1434_CR35","unstructured":"PrCosentyx\u00ae secukinumab injection. 75 mg\/0.5 mL, 150 mg\/1 mL, and 300 mg\/2 mL. Product Monograph. Montreal, QC, Canada: Novartis Pharmaceuticals Canada Inc.; 2024."},{"key":"1434_CR36","unstructured":"PrTALTZ\u00ae ixekizumab. Solution for injection. 80 mg\/1 mL. Subcutaneous use. Product monograph. Toronto, ON, Canada: Eli Lilly Canada Inc.; 2023."},{"issue":"2","key":"1434_CR37","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/bjd.19866","volume":"185","author":"D Thaci","year":"2021","unstructured":"Thaci D, Piaserico S, Warren RB, et al. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). Br J Dermatol. 2021;185(2):323\u201334.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1434_CR38","doi-asserted-by":"publisher","first-page":"e724","DOI":"10.1097\/JOM.0000000000002354","volume":"63","author":"M Mittal","year":"2021","unstructured":"Mittal M, Yang M, Shah M, Gao W, Carley C, Sherman BW. Impact of medication adherence on healthcare resource utilization, work loss, and associated costs in a privately insured employed population treated with adalimumab in the United States. J Occup Environ Med. 2021;63(10):e724\u201331.","journal-title":"J Occup Environ Med"},{"issue":"3","key":"1434_CR39","doi-asserted-by":"publisher","first-page":"A125","DOI":"10.1016\/j.jval.2016.03.1852","volume":"19","author":"H Tian","year":"2016","unstructured":"Tian H, Gilloteau I, Mollon P, McDwyer P, Lotya J. Biologics switching patterns and associated costs in psoriasis patients in a large commercially insured population in the United States. Value Health. 2016;19(3):A125.","journal-title":"Value Health"},{"key":"1434_CR40","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.2147\/PPA.S167508","volume":"12","author":"MJ Murage","year":"2018","unstructured":"Murage MJ, Tongbram V, Feldman SR, et al. Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Prefer Adherence. 2018;12:1483\u2013503.","journal-title":"Patient Prefer Adherence"},{"issue":"10","key":"1434_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15777","volume":"35","author":"J Yeung","year":"2022","unstructured":"Yeung J, Bourcier M, Gooderham MJ, et al. Management of moderate-to-severe plaque psoriasis with biologics: a treat-to-target position paper. Dermatol Ther. 2022;35(10): e15777.","journal-title":"Dermatol Ther"},{"issue":"5","key":"1434_CR42","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.jaad.2019.10.041","volume":"88","author":"S Muzumdar","year":"2023","unstructured":"Muzumdar S, Waldman R, Wu R, Kelsey A. In-office administration associated with increased drug survival of ustekinumab for chronic plaque psoriasis when compared with self-administration: a single-institution retrospective chart review. J Am Acad Dermatol. 2023;88(5):1111\u20133.","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01434-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01434-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01434-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:14:41Z","timestamp":1757175281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01434-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1434"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01434-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Vimal H. Prajapati has served as an advisor, consultant, and\/or speaker for AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez Bio, Arcutis Biotherapeutics, Aspen, Bausch Health\/Valeant BioScript Solutions, Boehringer Ingelheim, Bristol Myers Squibb, the Canadian Psoriasis Network, Celgene Corporation, Celltrion, Cipher, CorEvitas, Eli Lilly, Galderma, GSK, Homeocan, Incyte, JAMP Pharma, Janssen, J&J Innovative Medicine, Johnson & Johnson, Kevnue,\u00a0LEO Pharma, Medexus, Novartis, Organon, Pediapharm, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sun Pharma, Tribute, and UCB; been an investigator for AbbVie, Alumis, AnaptysBio, Apogee Therapeutics, Apollo Therapeutics, Arcutis Biotherapeutics, Arena, Asana, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Concert Pharmaceuticals (acquired by Sun Pharma in March 2023), CorEvitas, Dermavant Sciences, Dermira, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Nektar Therapeutics, Nimbus Lakshmi, Novartis, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Reistone Biopharma, Roche\/Genentech, Sanofi, Sun Pharma, Takeda, UCB, and Vyne Therapeutics; and received grants from AbbVie, Bausch Health, Janssen, LEO Pharma, Novartis, and Sanofi. Nicole Bellefontaine and Rommel Mangaser are employees of Bayshore HealthCare. Devi Gopalan is a former employee of Bayshore HealthCare. Pak Chan is an employee of Sun Pharma Canada Inc. Maxwell B. Sauder has served as an advisor, consultant, and\/or speaker for AbbVie, Alumis, Amgen, Apogee Therapeutics, Aralez Bio, Arcutis Biotherapeutics, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, the Canadian Psoriasis Network, Eli Lilly, Fresenius Kabi Canada, Galderma, Incyte, Janssen, Johnson & Johnson, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Sanofi, Sun Pharma, UCB, and Viatris; and has been an investigator for AbbVie, Alumis, Amgen, Bristol Myers Squibb, Dermavant Sciences, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Meiji Seika Pharma, Moberg Pharma, Novartis, Pfizer, Reistone Biopharma, Sanofi, and Ventyx Biosciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was exempt from institutional review board approval as it only used anonymized data. This study was conducted in accordance with ethical principles outlined in the Declaration of Helsinki, is consistent with Good Pharmacoepidemiology Practices and the Strengthening the Reporting of Observational Studies in Epidemiology guidelines, and conforms to applicable data and privacy laws. All patients participating in this study provided informed consent for their data to be used for research purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}